指南与共识药物相互作用

行业视角:药物开发中治疗性多肽的药物相互作用评估——EFPIA白皮书

Industry Perspective on Therapeutic Peptide Drug-Drug Interaction Assessments During Drug Development: A European Federation of Pharmaceutical Industries and Associations White Paper.
指南 / 共识 · Clin Pharmacol Ther · 2023-01-31

欧洲制药工业协会联合会(EFPIA)成立跨行业多肽DDI工作组,通过匿名调查10家领先公司及汇编近期获批多肽药物申报资料中的体外/临床DDI数据,发现多肽DDI研究时机差异大、体外CYP/转运体抑制研究几乎均为阴性且阳性结果无临床随访,>2 kDa多肽DDI可能性低,支持基于风险的方法。

要点

  • 多肽DDI评估缺乏监管指南,行业实践差异显著。
  • 调查中体外CYP/转运体抑制研究几乎均为阴性,阳性结果无临床随访。
  • 申报资料显示>2 kDa多肽DDI可能性低,可采用基于风险的方法。

核心结论

  • 多肽DDI评估领域存在显著空白与不确定性,>2 kDa多肽DDI可能性低,采用基于风险的方法合理。
  • 行业调查显示体外多肽DDI研究时机从早期研究到III期差异很大。
  • 调查中几乎所有体外CYP/转运体抑制研究均为阴性,少数阳性结果无临床随访研究。

研究设计与样本

  • EFPIA赞助下成立由10家领先公司专家组成的跨行业多肽DDI工作组。
  • 通过匿名调查参与多肽药物开发的公司了解当前DDI研究类型/时机。
  • 汇编近期获批多肽药物申报包中的体外/临床DDI数据建立数据库。

主要发现

  • 体外多肽DDI研究(若开展)的时机在受访公司间从早期研究到III期差异显著。
  • 调查中报告的几乎所有体外CYP/转运体抑制研究均为阴性。
  • 少数阳性结果未进行临床随访研究,其临床相关性存疑。
  • 申报资料显示>2 kDa多肽的DDI可能性低。

关键数值与推荐

  • 对于>2 kDa的多肽,药物开发中采用基于风险的方法进行评估是合理的。
  • 体外CYP/转运体抑制研究阳性结果缺乏临床随访,临床相关性待确认。

临床怎么用

  • 对于>2 kDa多肽,可考虑基于风险的方法减少不必要的DDI研究。
  • 体外CYP/转运体抑制阳性结果需谨慎解读,临床相关性不确定。

局限性

  • 调查基于匿名回复,可能存在应答偏倚。
  • 数据库仅包含近期获批多肽药物的申报资料,代表性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug-drug interaction (DDI) assessments are well defined in health authority guidelines for small molecule drugs, and US Food and Drug Administration (FDA) draft guidance is now available for therapeutic proteins. However, there are currently no regulatory guidelines outlining DDI assessments for therapeutic peptides, which poses significant uncertainty and challenges during drug development for this heterogenous class of molecules. A cross-industry peptide DDI working group consisting of experts from 10 leading companies was formed under the sponsorship of the European Federation of Pharmaceutical Industries and Associations. We aimed to capture the range of DDI studies undertaken for peptide drugs by (i) anonymously surveying relevant companies involved in peptide drug development to better understand DDI study type/timing currently performed and (ii) compiling a database containing in vitro / clinical DDI data from submission packages for recently approved peptide drugs. Our analyses highlight significant gaps and uncertainty in the field. For example, the reported timing of in vitro peptide DDI studies, if performed, vary substantially across responding companies from early research to phase III. Nearly all in vitro cytochrome P450 / transporter inhibition studies reported in the survey were negative. For the few positive hits reported, no clinical follow-up studies were performed, questioning the clinical relevance of these findings. Furthermore, available submission packages reveal DDI likelihood is low for peptides >2 kDa, making it reasonable to adopt a risk-based approach during drug development for larger peptides. By benchmarking the landscape of peptide DDI activities across the industry, we set the stage for future discussions with health authorities on harmonizing peptide DDI approaches.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Säll C, Argikar U, Fonseca K, et al. Industry Perspective on Therapeutic Peptide Drug-Drug Interaction Assessments During Drug Development: A European Federation of Pharmaceutical Industries and Associations White Paper. Clin Pharmacol Ther. 2023. PMID: 36633114. doi:10.1002/cpt.2847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。